Key Points
- Director Kevin Lobo bought 10,000 shares of GE HealthCare Technologies at $64.18 per share, spending about $641,800. The purchase lifted his stake to 14,363 shares, a 229.2% increase in ownership.
- GEHC stock opened at $64.18, near the director’s purchase price, but remains below its 50-day and 200-day moving averages of $68.20 and $76.10, respectively. The shares have traded between a 52-week low of $58.75 and a high of $89.77.
- The company recently reported quarterly EPS of $0.99, missing estimates, while revenue came in at $5.13 billion and rose 7.4% year over year. Analysts currently rate the stock a Moderate Buy with an average price target of $80.21.
GE HealthCare Technologies Inc. (NASDAQ:GEHC - Get Free Report) Director Kevin Lobo purchased 10,000 shares of the company's stock in a transaction dated Friday, May 22nd. The shares were bought at an average cost of $64.18 per share, for a total transaction of $641,800.00. Following the acquisition, the director owned 14,363 shares in the company, valued at approximately $921,817.34. The trade was a 229.20% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
GE HealthCare Technologies Stock Performance
Shares of NASDAQ GEHC opened at $64.18 on Wednesday. The firm's 50-day moving average price is $68.20 and its 200-day moving average price is $76.10. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95. The company has a market cap of $29.19 billion, a PE ratio of 15.35, a PEG ratio of 1.45 and a beta of 0.74.
GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The business had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter last year, the company earned $1.01 EPS. GE HealthCare Technologies's revenue for the quarter was up 7.4% on a year-over-year basis. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, analysts anticipate that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.
Institutional Investors Weigh In On GE HealthCare Technologies
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC bought a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $26,000. Optima Capital LLC bought a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $27,000. Godfrey Financial Associates Inc. bought a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $27,000. Montag A & Associates Inc. raised its stake in GE HealthCare Technologies by 105.4% during the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company's stock worth $28,000 after acquiring an additional 175 shares during the period. Finally, Transamerica Financial Advisors LLC raised its stake in GE HealthCare Technologies by 331.6% during the 4th quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company's stock worth $28,000 after acquiring an additional 262 shares during the period. Institutional investors own 82.06% of the company's stock.
Analysts Set New Price Targets
GEHC has been the topic of several recent research reports. The Goldman Sachs Group cut shares of GE HealthCare Technologies from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $81.00 to $65.00 in a research note on Thursday, April 30th. Morgan Stanley increased their price objective on shares of GE HealthCare Technologies from $80.00 to $85.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 4th. Evercore set a $80.00 price objective on shares of GE HealthCare Technologies in a research note on Thursday, April 30th. UBS Group upgraded shares of GE HealthCare Technologies from a "sell" rating to a "neutral" rating and lowered their price objective for the stock from $75.00 to $69.00 in a research note on Thursday, May 21st. Finally, Weiss Ratings cut shares of GE HealthCare Technologies from a "hold (c)" rating to a "hold (c-)" rating in a research note on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $80.21.
View Our Latest Report on GE HealthCare Technologies
About GE HealthCare Technologies
(
Get Free Report)
GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.
In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
